Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fennec Pharmaceuticals ( (TSE:FRX) ) has shared an announcement.
Fennec Pharmaceuticals reported record 2025 results, with PEDMARK net product sales rising 50% year over year to $44.6 million and fourth-quarter sales up 75% to $13.8 million, underscoring accelerating adoption across key accounts and patient segments. Management highlighted strong execution through expanded field teams, all-time high patient enrollments and conversion rates, and strengthened finances following oversubscribed $42 million equity offerings and full debt redemption.
The company advanced its clinical and real-world evidence strategy for PEDMARK, including positive topline data from the STS-J01 Phase 2/3 study in Japan in pediatric and AYA patients and new real-world data in adults with head and neck cancer demonstrating safe integration with cisplatin regimens. Additional institution-led trials at City of Hope and Tampa General Hospital are evaluating PEDMARK across broader adult and AYA populations, positioning Fennec to potentially extend PEDMARK’s use across new tumor types and support its bid to reshape the standard of care in cisplatin-based oncology treatment.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies to prevent chemotherapy-induced side effects, with a primary emphasis on PEDMARK, its formulation aimed at reducing cisplatin-induced hearing loss. The company targets pediatric, adolescent and young adult, and increasingly adult cancer patients receiving cisplatin-based treatments, with growing engagement across key U.S. cancer centers and international markets such as Japan.
Average Trading Volume: 780
Technical Sentiment Signal: Hold
Current Market Cap: C$346.5M
See more data about FRX stock on TipRanks’ Stock Analysis page.